BR0308305A - Dosage controlled release formulas - Google Patents

Dosage controlled release formulas

Info

Publication number
BR0308305A
BR0308305A BR0308305-5A BR0308305A BR0308305A BR 0308305 A BR0308305 A BR 0308305A BR 0308305 A BR0308305 A BR 0308305A BR 0308305 A BR0308305 A BR 0308305A
Authority
BR
Brazil
Prior art keywords
zero
order
controlled release
metered
dosed
Prior art date
Application number
BR0308305-5A
Other languages
Portuguese (pt)
Inventor
Itzhak E Lerner
Vered Rosemberger
Ofer Aqua
Moshe Flashner-Barak
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of BR0308305A publication Critical patent/BR0308305A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B30—PRESSES
    • B30B—PRESSES IN GENERAL
    • B30B11/00—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
    • B30B11/34—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses for coating articles, e.g. tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"FóRMULAS DOSADAS DE LIBERAçãO CONTROLADA". Provê-se uma fórmula farmacêutica dosada de liberação de ordem zero para administração oral a um paciente, consistindo de um comprimido central encapado em uma capa anular de material em pó ou granular prensado. Uma incorporação preferencial da fórmula farmacêutica dosada de liberação de ordem zero é uma fórmula farmacêutica dosada sólida que reduz o contato do ingrediente ativo na forma sólida com a mucosa que forra o trato gastrointestinal, o que é especialmente vantajoso para a administração de uma droga ulcerante. Provê-se também um processo para a fabricação da fórmula farmacêutica dosada de liberação de ordem zero."DOSED CONTROLLED RELEASE FORMULAS". A zero-order dosed pharmaceutical formulation for oral administration to a patient is provided, consisting of a central tablet enclosed in an annular shell of pressed powder or granular material. A preferred embodiment of the zero-order metered pharmaceutical formula is a solid metered pharmaceutical formula that reduces contact of the active ingredient in solid form with the mucosa lining the gastrointestinal tract, which is especially advantageous for the administration of an ulcerant drug. A process is also provided for the manufacture of the zero order metered dosage pharmaceutical formula.

BR0308305-5A 2002-03-04 2003-03-03 Dosage controlled release formulas BR0308305A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36182102P 2002-03-04 2002-03-04
US29161902A 2002-11-12 2002-11-12
PCT/US2003/006591 WO2003075893A1 (en) 2002-03-04 2003-03-03 Controlled release dosage forms

Publications (1)

Publication Number Publication Date
BR0308305A true BR0308305A (en) 2004-12-28

Family

ID=27807664

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308305-5A BR0308305A (en) 2002-03-04 2003-03-03 Dosage controlled release formulas

Country Status (13)

Country Link
EP (1) EP1492508A4 (en)
JP (1) JP2005524670A (en)
KR (1) KR20100049695A (en)
CN (1) CN1649569B (en)
AU (2) AU2003217909C1 (en)
BR (1) BR0308305A (en)
CA (1) CA2477701A1 (en)
EA (1) EA005866B1 (en)
IL (1) IL163887A0 (en)
MX (1) MXPA04008536A (en)
NO (1) NO20044188L (en)
NZ (1) NZ535083A (en)
WO (1) WO2003075893A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
AU2003249478A1 (en) * 2002-07-19 2004-02-09 Ranbaxy Laboratories Limited Taste masked sumatriptan tablets and processes for their preparation
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
MXPA05005038A (en) * 2002-11-12 2005-07-01 Teva Pharma Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or bucally.
WO2005046978A1 (en) * 2003-11-14 2005-05-26 Sanwa Kagaku Kenkyusho Co., Ltd. Method of manufacturing nucleated molding
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
CA2555406A1 (en) * 2004-02-19 2005-09-01 Teva Pharmaceutical Industries, Ltd. Improved therapy using a combination of raloxifene and alendronate
KR100701409B1 (en) 2004-11-26 2007-03-30 한국유나이티드제약 주식회사 Pharmaceutical formulations containing sumatriptan succinate
CA2733787C (en) 2008-08-15 2016-09-06 Depomed, Inc. Gastric retentive pharmaceutical compositions for treatment and prevention of cns disorders
CN103948556A (en) * 2014-04-08 2014-07-30 闻晓光 Novel controlled release tablet
JP6878417B2 (en) * 2016-02-17 2021-05-26 トリアステック インコーポレイテッド Dosage forms and their use
CN110604724A (en) * 2019-10-22 2019-12-24 恒诚制药集团淮南有限公司 Enteric mesalazine sustained-release tablet and preparation method thereof
US20240122177A1 (en) * 2022-10-13 2024-04-18 Clarke Mosquito Control Products, Inc. Insecticidal tablet compositions
JP2024083720A (en) * 2022-12-12 2024-06-24 パナソニックＩｐマネジメント株式会社 Sustained-release solid medical agent for water treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB972128A (en) * 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
JPS61243016A (en) * 1985-04-19 1986-10-29 Katsumi Takada Tablet having columnar part containing active constituent
GB8514666D0 (en) * 1985-06-11 1985-07-10 Coopers Animal Health Agent delivery systems
JPS6253918A (en) * 1985-09-02 1987-03-09 Katsumi Takada Tablet containing embedded columnar part containing active component
DE4431653C2 (en) * 1994-09-06 2000-01-20 Lohmann Therapie Syst Lts Coated tablet for the controlled release of active substances, a process for their preparation and their use
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
JP3962108B2 (en) * 1995-04-03 2007-08-22 中外製薬株式会社 Sucralfate-containing pharmaceutical composition
CA2184316A1 (en) * 1995-09-12 1997-03-13 Wei-Chi Liao Buccal delivery system for therapeutic agents
ATE214597T1 (en) * 1997-12-19 2002-04-15 Merck Patent Gmbh MULTI-LAYER TABLET CONTAINING PROBIOTIC MICROORGANISMS SUCH AS LACTOBACILLI OR BIFIDOBACTERIA
DE69821984T2 (en) * 1997-12-22 2004-12-30 Schering Corp. PREPARATION CONTAINS A MOLECULAR DISPERSION WITH INCREASED BIOAVAILABILITY
JP4748839B2 (en) * 1999-03-25 2011-08-17 大塚製薬株式会社 Cilostazol preparation
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
JP2004513877A (en) * 2000-06-28 2004-05-13 アンジオジェニックス，アイエヌシー． Controlled release arginine preparation
NZ534104A (en) * 2001-12-24 2007-03-30 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material

Also Published As

Publication number Publication date
AU2003217909C1 (en) 2009-06-11
EA005866B1 (en) 2005-06-30
IL163887A0 (en) 2005-12-18
NO20044188L (en) 2004-12-03
EP1492508A1 (en) 2005-01-05
NZ535083A (en) 2007-06-29
JP2005524670A (en) 2005-08-18
AU2003217909B2 (en) 2008-10-30
CA2477701A1 (en) 2003-09-18
WO2003075893A1 (en) 2003-09-18
CN1649569A (en) 2005-08-03
MXPA04008536A (en) 2005-09-08
CN1649569B (en) 2010-05-05
EA200401097A1 (en) 2005-04-28
KR20100049695A (en) 2010-05-12
AU2009200353A1 (en) 2009-02-19
AU2003217909A1 (en) 2003-09-22
EP1492508A4 (en) 2009-05-06

Similar Documents

Publication Publication Date Title
BR0215413A (en) Formula dosed with a central active ingredient tablet encased in a pressed annular layer of powder or granular material and process and tooling for its production.
BR0308305A (en) Dosage controlled release formulas
JP4435424B2 (en) Tablets that disintegrate quickly in the oral cavity
BRPI0513598A (en) enteric release coated tablet dosage forms
BRPI0518266A2 (en) modified-release oral medicinal product of at least one active ingredient in multi-capsule form
SE9804314D0 (en) New pharmaceutical formulation
JP5336553B2 (en) Formulation with accurate dose division function
KR20120112644A (en) Loxoprofen-containing pharmaceutical composition
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
IS7006A (en) Dihydrogen 3-piperidinopropiophenone and medicinal products containing said compounds
BR9807992A (en) Pills to swallow which comprise paracetamol
AP2003002763A0 (en) Controlled release formulations for oral administration
HUP0301390A2 (en) Oral pharmaceutical composition containing valsartan
BR0013719A (en) Controlled-release oral dosage, suitable for oral administration
ATE401075T1 (en) MEDICINAL PRODUCT CONTAINING CYTISINE
JP6009967B2 (en) Solid preparation
PE20030830A1 (en) AMBROXOL FOR THE TREATMENT OF PAINFUL STATES IN THE ORAL CAVITY AND PHARYNGEAL
TWI731846B (en) Ultra-high-speed disintegrating tablet and manufacturing method thereof
BRPI0407438A (en) Therapeutic system comprising amoxicillin and clavulanic acid
JP2007224021A (en) Fast-disintegrating tablet containing iguratimod
TWI762450B (en) Ultra-high-speed disintegrating tablet and its manufacturing method
AR033331A1 (en) POLYMORPH FORMS OF A AZABICICLO CITRATE [2,2,2] OCTAN-3-AMINA, ITS PHARMACEUTICAL COMPOSITIONS, PROCESSING PROCEDURE AND PROCEDURE FOR PRODUCTION.
JP2007051093A (en) Preparation facilitating dosage control
US20080063709A1 (en) Pharmaceutical compositions having novel scoring patterns
JP2018100259A (en) Solid preparation

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/195, 31/216, 31/4045, 31/433, 31/663, 45/06, 47/10, 47/16, 47/22, 47/26, 47/32, 47/34, 47/38, 9/20, 9/22, 9/24, 9/26; A61P 19/00, 25/00, 5/00, 9/00

Ipc: A61K 31/195 (2011.01), A61K 31/216 (2011.01), A61K

B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A, 10A E 11A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.